Aneurysmal Subarachnoid HemorrhageLongTEAMNCT04785976
Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage
An observational study of Aneurysmal Subarachnoid Hemorrhage, run by Beijing Tiantan Hospital at 2 sites in China.
Trial summary
Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Aneurysmal Subarachnoid Hemorrhage
- What is being tested?
- Surgical clipping and endovascular coiling
- Type of treatment
- Surgery or procedure
- How many people
- 5,000 participants
- Where
- 2 sitesChina
- Study dates
- 1 Apr 2012to 1 Apr 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry
Who may be able to join
- All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry.
Who cannot join
- None
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Recruiting
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070
Runting Li, MD, +8615753166690, 1011168227@qq.com
Xiaolin Chen, MD, +8613810624845, xiaolinchen488@hotmail.com
- Recruiting
The First People's Hospital of Neijiang
Neijiang, Sichuan
Qian Wu, MD, wsq9385@163.com
About this study
Official title: Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage: an MDT- Based Multicenter Cohort Study
Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden.
This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Being tested
- Surgical clipping and endovascular coiling
- Medical subject headings
- Subarachnoid Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical clipping and endovascular coilingProcedure or surgery
Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
| Study group | Role | What they receive |
|---|---|---|
| Surgical clipping | Not described Receives: Procedure: Surgical clipping and endovascular coiling | |
| Endovascular coiling | Not described Receives: Procedure: Surgical clipping and endovascular coiling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of >2.
Measured: 10 days after the procedure
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Measured: 3 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Measured: 6 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Measured: 12 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Measured: 24 months
Secondary outcomes (10)
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at discharge,defined as changes in thinking, emotion, will and behavior.
Measured: 10 days after the procedure
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 3 months, defined as changes in thinking, emotion, will and behavior.
Measured: 3 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 6 months, defined as changes in thinking, emotion, will and behavior.
Measured: 6 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 12 months, defined as changes in thinking, emotion, will and behavior.
Measured: 12 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 24 months, defined as changes in thinking, emotion, will and behavior.
Measured: 24 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at discharge.
Measured: 10 days after the procedure
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 3 months.
Measured: 3 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 6 months.
Measured: 6 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 12 months.
Measured: 12 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 24 months.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2021
- Study start1 Apr 2012
- Primary completion1 Mar 2032 (estimated)
- Study completion1 Apr 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Aneurysmal Subarachnoid HemorrhageStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Peking University International Hospital
- Responsible party
- Principal investigator, yuanli Zhao, Beijing Tiantan Hospital
- Investigators
- Fa Lin, MD, Principal investigator, Beijing Tiantan HospitalYuanli Zhao, MD, Study chair, Beijing Tiantan HospitalJizong Zhao, MD, Study chair, Beijing Tiantan HospitalRunting Li, MD, Principal investigator, Beijing Tiantan HospitalXiaolin Chen, MD, Study director, Beijing Tiantan HospitalYu Chen, MD, Principal investigator, Beijing Tiantan HospitalJunlin Lu, MD, Principal investigator, Beijing Tiantan HospitalZhipeng Li, MD, Principal investigator, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04785976
- Sponsor's protocol ID
- KY 2020-11-26
- Acronym
- LongTEAM
- Status last verified
- Nov 2023
- First submitted
- 1 Feb 2021
- Last updated
- 1 Dec 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The individual participant data (IPD) of this study are available from the principal investigator upon reasonable request.
Publications
Tang X, Wang X, Zhu B, Zhou L, Chen X. The prognostic significance of uric acid to albumin ratio in patients with aneurysmal subarachnoid hemorrhage following surgical clipping or endovascular interventions: insights from a large cohort study. Front Neurol. 2026 Jan 12;16:1648805. doi: 10.3389/fneur.2025.1648805. eCollection 2025.
PubMed 41602990Yu T, Lau TY, Liu Y, Li R, Lin F, Song Z, Zhu Q, Chen Y, Li T, Jing J, Chen X. Low-Field Portable MRI Detects Developmental Pattern of Ultraearly Cerebral Infarction in aSAH. Stroke. 2026 Mar;57(3):721-731. doi: 10.1161/STROKEAHA.125.052474. Epub 2025 Dec 11.
PubMed 41376582Tang X, Zhu B, Liu M, Lin F, Li R, Song W, Xue J, Zhou L, Chen X. Increased triglyceride-glucose index is associated with adverse functional outcome for patients with aneurysmal subarachnoid hemorrhage after surgical clipping and endovascular coiling: insights from a large cohort study. Front Neurol. 2025 Sep 10;16:1622819. doi: 10.3389/fneur.2025.1622819. eCollection 2025.
PubMed 41001201Yang Y, Zhu B, Lin F, Li R, Chen X. Association between geriatric nutritional risk index and clinical outcome of elderly aneurysmal subarachnoid hemorrhage patients: insights from a large cohort study. Neurosurg Rev. 2025 Feb 4;48(1):169. doi: 10.1007/s10143-025-03209-6.
PubMed 39903290Li R, Lin F, Chen Y, Lu J, Yang J, Han H, Yuan K, Wang K, Yan D, Li R, He S, Li Z, Zhang H, Chen X, Ma L, Zhao Y, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Li Y, Wang S, Chen X, Zhao Y. The effect of sex differences on complications and 90-day outcomes after aneurysmal subarachnoid hemorrhage: a propensity score-matched analysis. Neurosurg Rev. 2022 Oct;45(5):3339-3347. doi: 10.1007/s10143-022-01836-x. Epub 2022 Jul 23.
PubMed 35870093Li R, Lin F, Chen Y, Lu J, Han H, Ma L, Zhao Y, Yan D, Li R, Yang J, He S, Li Z, Zhang H, Yuan K, Wang K, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Zhao Y, Zhang Y, Li Y, Wang S, Chen X, Zhao Y. A 90-Day Prognostic Model Based on the Early Brain Injury Indicators after Aneurysmal Subarachnoid Hemorrhage: the TAPS Score. Transl Stroke Res. 2023 Apr;14(2):200-210. doi: 10.1007/s12975-022-01033-4. Epub 2022 May 14.
PubMed 35567655Li R, Lin F, Chen Y, Lu J, Han H, Ma L, Zhao Y, Yan D, Li R, Yang J, He S, Li Z, Zhang H, Yuan K, Wang K, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Zhao Y, Zhang Y, Li Y, Wang S, Chen X, Zhao Y. Elevated blood hemoglobin on admission as an independent predictor of unfavorable outcomes in patients with aneurysmal subarachnoid hemorrhage. Neurosurg Rev. 2022 Aug;45(4):2689-2699. doi: 10.1007/s10143-022-01780-w. Epub 2022 Apr 2.
PubMed 35366711Yang J, Lu J, Li R, Lin F, Chen Y, Han H, Yan D, Li R, Li Z, Zhang H, Yuan K, Li H, Zhang L, Shi G, Zhou J, Wang S, Zhao Y, Chen X. Application of Intracranial Pressure-Directed Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage. Front Aging Neurosci. 2022 Mar 14;14:831994. doi: 10.3389/fnagi.2022.831994. eCollection 2022.
PubMed 35360218Lin F, Chen Y, He Q, Zeng C, Zhang C, Chen X, Zhao Y, Wang S, Zhao J. Prognostic Value of Elevated Cardiac Troponin I After Aneurysmal Subarachnoid Hemorrhage. Front Neurol. 2021 May 31;12:677961. doi: 10.3389/fneur.2021.677961. eCollection 2021.
PubMed 34135855
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage: an MDT- Based Multicenter Cohort Study
- ClinicalTrials.gov ID
- NCT04785976
- Acronym / sponsor ID
- LongTEAM / KY 2020-11-26
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- Peking University International Hospital
- Study start
- 1 Apr 2012 (actual)
- Primary completion
- 1 Mar 2032 (estimated)
- Study completion
- 1 Apr 2032 (estimated)
- First posted
- 8 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden.
This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Surgical clipping | – | Procedure: Surgical clipping and endovascular coiling |
| Endovascular coiling | – | Procedure: Surgical clipping and endovascular coiling |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry
Key inclusion criteria (1 listed)
- All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical clipping and endovascular coilingSurgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing. | Procedure or surgery | Endovascular coiling, Surgical clipping |
Primary outcome
Unfavorable neurological outcome (mRS>2)
Time frame: 10 days after the procedure
Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of >2.
Unfavorable neurological outcome (mRS>2)
Time frame: 3 months
Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Unfavorable neurological outcome (mRS>2)
Time frame: 6 months
Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Unfavorable neurological outcome (mRS>2)
Time frame: 12 months
Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
Unfavorable neurological outcome (mRS>2)
Time frame: 24 months
Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2.
10 secondary outcomes
Cognitive deficits
Time frame: 10 days after the procedure
Cognitive deficits
Time frame: 3 months
Cognitive deficits
Time frame: 6 months
Cognitive deficits
Time frame: 12 months
Cognitive deficits
Time frame: 24 months
Major adverse cardiac or cerebrovascular events
Time frame: 10 days after the procedure
Major adverse cardiac or cerebrovascular events
Time frame: 3 months
Major adverse cardiac or cerebrovascular events
Time frame: 6 months
Major adverse cardiac or cerebrovascular events
Time frame: 12 months
Major adverse cardiac or cerebrovascular events
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2023.
- Derived from this study: PubMed 41602990Tang X, Wang X, Zhu B, Zhou L, Chen X. The prognostic significance of uric acid to albumin ratio in patients with aneurysmal subarachnoid hemorrhage following surgical clipping or endovascular interventions: insights from a large cohort study. Front Neurol. 2026 Jan 12;16:1648805. doi: 10.3389/fneur.2025.1648805. eCollection 2025.
- Derived from this study: PubMed 41376582Yu T, Lau TY, Liu Y, Li R, Lin F, Song Z, Zhu Q, Chen Y, Li T, Jing J, Chen X. Low-Field Portable MRI Detects Developmental Pattern of Ultraearly Cerebral Infarction in aSAH. Stroke. 2026 Mar;57(3):721-731. doi: 10.1161/STROKEAHA.125.052474. Epub 2025 Dec 11.
- Derived from this study: PubMed 41001201Tang X, Zhu B, Liu M, Lin F, Li R, Song W, Xue J, Zhou L, Chen X. Increased triglyceride-glucose index is associated with adverse functional outcome for patients with aneurysmal subarachnoid hemorrhage after surgical clipping and endovascular coiling: insights from a large cohort study. Front Neurol. 2025 Sep 10;16:1622819. doi: 10.3389/fneur.2025.1622819. eCollection 2025.
- Derived from this study: PubMed 39903290Yang Y, Zhu B, Lin F, Li R, Chen X. Association between geriatric nutritional risk index and clinical outcome of elderly aneurysmal subarachnoid hemorrhage patients: insights from a large cohort study. Neurosurg Rev. 2025 Feb 4;48(1):169. doi: 10.1007/s10143-025-03209-6.
- Derived from this study: PubMed 35870093Li R, Lin F, Chen Y, Lu J, Yang J, Han H, Yuan K, Wang K, Yan D, Li R, He S, Li Z, Zhang H, Chen X, Ma L, Zhao Y, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Li Y, Wang S, Chen X, Zhao Y. The effect of sex differences on complications and 90-day outcomes after aneurysmal subarachnoid hemorrhage: a propensity score-matched analysis. Neurosurg Rev. 2022 Oct;45(5):3339-3347. doi: 10.1007/s10143-022-01836-x. Epub 2022 Jul 23.
- Derived from this study: PubMed 35567655Li R, Lin F, Chen Y, Lu J, Han H, Ma L, Zhao Y, Yan D, Li R, Yang J, He S, Li Z, Zhang H, Yuan K, Wang K, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Zhao Y, Zhang Y, Li Y, Wang S, Chen X, Zhao Y. A 90-Day Prognostic Model Based on the Early Brain Injury Indicators after Aneurysmal Subarachnoid Hemorrhage: the TAPS Score. Transl Stroke Res. 2023 Apr;14(2):200-210. doi: 10.1007/s12975-022-01033-4. Epub 2022 May 14.
- Derived from this study: PubMed 35366711Li R, Lin F, Chen Y, Lu J, Han H, Ma L, Zhao Y, Yan D, Li R, Yang J, He S, Li Z, Zhang H, Yuan K, Wang K, Hao Q, Ye X, Wang H, Li H, Zhang L, Shi G, Zhou J, Zhao Y, Zhang Y, Li Y, Wang S, Chen X, Zhao Y. Elevated blood hemoglobin on admission as an independent predictor of unfavorable outcomes in patients with aneurysmal subarachnoid hemorrhage. Neurosurg Rev. 2022 Aug;45(4):2689-2699. doi: 10.1007/s10143-022-01780-w. Epub 2022 Apr 2.
- Derived from this study: PubMed 35360218Yang J, Lu J, Li R, Lin F, Chen Y, Han H, Yan D, Li R, Li Z, Zhang H, Yuan K, Li H, Zhang L, Shi G, Zhou J, Wang S, Zhao Y, Chen X. Application of Intracranial Pressure-Directed Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage. Front Aging Neurosci. 2022 Mar 14;14:831994. doi: 10.3389/fnagi.2022.831994. eCollection 2022.
- Derived from this study: PubMed 34135855Lin F, Chen Y, He Q, Zeng C, Zhang C, Chen X, Zhao Y, Wang S, Zhao J. Prognostic Value of Elevated Cardiac Troponin I After Aneurysmal Subarachnoid Hemorrhage. Front Neurol. 2021 May 31;12:677961. doi: 10.3389/fneur.2021.677961. eCollection 2021.
- Individual participant dataSharing planned: Yes. The individual participant data (IPD) of this study are available from the principal investigator upon reasonable request.
Related trials for Aneurysmal Subarachnoid Hemorrhage
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fa Lin, MD principal investigator
Beijing Tiantan Hospital
Yuanli Zhao, MD study chair
Beijing Tiantan Hospital
Jizong Zhao, MD study chair
Beijing Tiantan Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aneurysmal Subarachnoid Hemorrhage, run by Beijing Tiantan Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Runting Li, MD (+8615753166690 ext. +8613681107240, 1011168227@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Unfavorable neurological outcome (mRS>2) (time frame: 10 days after the procedure). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04785976, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2023.